Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
BIOCON | SUN PHARMA | BIOCON / SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.6 | 76.1 | 42.8% | View Chart |
P/BV | x | 3.9 | 3.2 | 119.4% | View Chart |
Dividend Yield | % | 0.3 | 0.7 | 38.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
SUN PHARMA Mar-20 |
BIOCON / SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 484 | 146.1% | |
Low | Rs | 554 | 315 | 175.7% | |
Sales per share (Unadj.) | Rs | 91.9 | 136.9 | 67.2% | |
Earnings per share (Unadj.) | Rs | 16.7 | 17.5 | 95.8% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 26.0 | 93.0% | |
Dividends per share (Unadj.) | Rs | 1.00 | 4.00 | 25.0% | |
Dividend yield (eoy) | % | 0.2 | 1.0 | 15.8% | |
Book value per share (Unadj.) | Rs | 101.6 | 188.7 | 53.9% | |
Shares outstanding (eoy) | m | 600.00 | 2,399.26 | 25.0% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 2.9 | 235.0% | |
Avg P/E ratio | x | 37.7 | 22.9 | 164.8% | |
P/CF ratio (eoy) | x | 26.1 | 15.4 | 169.7% | |
Price / Book Value ratio | x | 6.2 | 2.1 | 292.9% | |
Dividend payout | % | 6.0 | 22.9 | 26.1% | |
Avg Mkt Cap | Rs m | 378,330 | 958,864 | 39.5% | |
No. of employees | `000 | 6.1 | 17.8 | 34.5% | |
Total wages/salary | Rs m | 11,653 | 63,624 | 18.3% | |
Avg. sales/employee | Rs Th | 8,994.3 | 18,490.6 | 48.6% | |
Avg. wages/employee | Rs Th | 1,900.7 | 3,582.6 | 53.1% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 2,357.6 | 69.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 328,375 | 16.8% | |
Other income | Rs m | 1,444 | 6,360 | 22.7% | |
Total revenues | Rs m | 56,588 | 334,735 | 16.9% | |
Gross profit | Rs m | 15,883 | 69,898 | 22.7% | |
Depreciation | Rs m | 4,478 | 20,528 | 21.8% | |
Interest | Rs m | 709 | 3,027 | 23.4% | |
Profit before tax | Rs m | 12,140 | 52,702 | 23.0% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 2,123 | 8,228 | 25.8% | |
Profit after tax | Rs m | 10,026 | 41,868 | 23.9% | |
Gross profit margin | % | 28.8 | 21.3 | 135.3% | |
Effective tax rate | % | 17.5 | 15.6 | 112.0% | |
Net profit margin | % | 18.2 | 12.8 | 142.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 316,542 | 15.2% | |
Current liabilities | Rs m | 30,376 | 157,064 | 19.3% | |
Net working cap to sales | % | 32.4 | 48.6 | 66.7% | |
Current ratio | x | 1.6 | 2.0 | 78.8% | |
Inventory Days | Days | 68 | 88 | 78.0% | |
Debtors Days | Days | 86 | 105 | 81.7% | |
Net fixed assets | Rs m | 64,130 | 243,102 | 26.4% | |
Share capital | Rs m | 3,000 | 2,399 | 125.0% | |
"Free" reserves | Rs m | 57,980 | 450,245 | 12.9% | |
Net worth | Rs m | 60,980 | 452,645 | 13.5% | |
Long term debt | Rs m | 15,766 | 20,289 | 77.7% | |
Total assets | Rs m | 121,924 | 682,525 | 17.9% | |
Interest coverage | x | 18.1 | 18.4 | 98.4% | |
Debt to equity ratio | x | 0.3 | 0 | 576.8% | |
Sales to assets ratio | x | 0.5 | 0.5 | 94.0% | |
Return on assets | % | 8.8 | 6.6 | 133.9% | |
Return on equity | % | 16.4 | 9.2 | 177.8% | |
Return on capital | % | 16.8 | 11.2 | 149.2% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 74,219 | 20.9% | |
Fx outflow | Rs m | 10,399 | 27,964 | 37.2% | |
Net fx | Rs m | 5,107 | 46,255 | 11.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 65,548 | 17.6% | |
From Investments | Rs m | -7,138 | -25,888 | 27.6% | |
From Financial Activity | Rs m | -2,417 | -57,151 | 4.2% | |
Net Cashflow | Rs m | 2,103 | -13,857 | -15.2% |
Indian Promoters | % | 40.4 | 63.7 | 63.4% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 5.1 | 163.7% | |
FIIs | % | 10.7 | 23.0 | 46.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 8.3 | 239.8% | |
Shareholders | 109,995 | 133,026 | 82.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | 7.5% |
Compare BIOCON With: ORCHID PHARMA CIPLA TORRENT PHARMA SUVEN LIFE SCIENCES WYETH
Compare BIOCON With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More